Skip to main content
Erschienen in: Annals of Surgical Oncology 9/2010

01.09.2010 | Colorectal Cancer

Clinical Significance of CEA and CA19-9 in Postoperative Follow-up of Colorectal Cancer

verfasst von: Tomomi Yakabe, MD, Yuji Nakafusa, MD, PhD, Kenji Sumi, MD, PhD, Atsushi Miyoshi, MD, PhD, Yoshihiko Kitajima, MD, PhD, Seiji Sato, MD, PhD, Hirokazu Noshiro, MD, PhD, Kohji Miyazaki, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

We evaluated the efficiency of CEA and CA19-9 as tools for diagnosing recurrence in the postoperative surveillance of colorectal cancer.

Materials and Methods

A total of 227 patients who underwent curative resection for colorectal cancer between 1999 and 2003 at our hospital received complete follow-up according to the schedule determined prospectively. Using receiver operating characteristic (ROC) analysis, performance of postoperative values of CEA or CA19-9 for detecting recurrence was assessed.

Results

The sensitivity (1.000) and specificity (0.978) of the postoperative values of CEA in the high preoperative CEA group were very high. Even in the normal preoperative CEA group, the area under the curve (AUC) of the ROC curve of CEA (0.740, 95% confidence interval [95% CI], 0.628–0.852) was significantly larger than 0.5 (P < 0.001). The postoperative values of CA19-9 showed high sensitivity (0.833) and specificity (0.900) in the high preoperative CA19-9 group, while the AUC of the ROC curve of the normal preoperative group was as small as 0.510 (95% CI, 0.376–0.644). In the high preoperative CA19-9 group, however, there was no significant difference between the AUC of CA19-9 (0.904, 95% CI, 0.786–1.000) and that of CEA (0.869, 95% CI, 0.744–0.994) (P = 0.334).

Conclusions

The measurement of CEA is an efficient way to detect recurrence. The efficiency of measuring CA19-9 for the purpose of detecting recurrence is low, especially in patients with a normal level of preoperative CA19-9. Even in patients with a high preoperative level of CA19-9, CEA might be able to fill the role of CA19-9.
Literatur
1.
Zurück zum Zitat Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50:1783–99.CrossRefPubMed Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50:1783–99.CrossRefPubMed
2.
Zurück zum Zitat Rodriguez-Moranta F, Saló J, Arcusa A, Boadas J, Piñol V, Bessa X, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol. 2006;24:386–93.CrossRefPubMed Rodriguez-Moranta F, Saló J, Arcusa A, Boadas J, Piñol V, Bessa X, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol. 2006;24:386–93.CrossRefPubMed
3.
Zurück zum Zitat Desch CE, Benson AB 3rd, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005;23:8512–9.CrossRefPubMed Desch CE, Benson AB 3rd, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005;23:8512–9.CrossRefPubMed
4.
Zurück zum Zitat Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003;3:26. Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003;3:26.
5.
6.
Zurück zum Zitat Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg KG. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum. 1995;38:619–26.CrossRefPubMed Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg KG. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum. 1995;38:619–26.CrossRefPubMed
7.
Zurück zum Zitat Grossmann I, de Bock GH, van de Velde CJ, Kievit J, Wiggers T. Results of a national survey among Dutch surgeons treating patients with colorectal carcinoma. Current opinion about follow-up, treatment of metastasis, and reasons to revise follow-up practice. Colorectal Dis. 2007;9:787–92.CrossRefPubMed Grossmann I, de Bock GH, van de Velde CJ, Kievit J, Wiggers T. Results of a national survey among Dutch surgeons treating patients with colorectal carcinoma. Current opinion about follow-up, treatment of metastasis, and reasons to revise follow-up practice. Colorectal Dis. 2007;9:787–92.CrossRefPubMed
8.
Zurück zum Zitat Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2007:CD002200. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2007:CD002200.
9.
Zurück zum Zitat Secco GB, Fardelli R, Gianquinto D, Bonfante P, Baldi E, Ravera G, et al.. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol. 2002;28:418–23.CrossRefPubMed Secco GB, Fardelli R, Gianquinto D, Bonfante P, Baldi E, Ravera G, et al.. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol. 2002;28:418–23.CrossRefPubMed
10.
Zurück zum Zitat Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al.. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313–27.CrossRefPubMed Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al.. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313–27.CrossRefPubMed
11.
Zurück zum Zitat Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003;39:718–27.CrossRefPubMed Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003;39:718–27.CrossRefPubMed
12.
Zurück zum Zitat Kouri M, Pyrhonen S, Kuusela P. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol. 1992;49:78–85.CrossRefPubMed Kouri M, Pyrhonen S, Kuusela P. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol. 1992;49:78–85.CrossRefPubMed
13.
Zurück zum Zitat Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, et al. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res. 2005;124:169–74.CrossRefPubMed Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, et al. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res. 2005;124:169–74.CrossRefPubMed
14.
Zurück zum Zitat Morita S, Nomura T, Fukushima Y, Morimoto T, Hiraoka N, Shibata N. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer? Dis Colon Rectum. 2004;47:227–32.CrossRefPubMed Morita S, Nomura T, Fukushima Y, Morimoto T, Hiraoka N, Shibata N. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer? Dis Colon Rectum. 2004;47:227–32.CrossRefPubMed
15.
Zurück zum Zitat Eche N, Pichon MF, Quillien V, Gory-Delabaere G, Riedinger JM, Basuyau JP, et al. [Standards, options and recommendations for tumor markers in colorectal cancer]. Bull Cancer. 2001;88:1177–206.PubMed Eche N, Pichon MF, Quillien V, Gory-Delabaere G, Riedinger JM, Basuyau JP, et al. [Standards, options and recommendations for tumor markers in colorectal cancer]. Bull Cancer. 2001;88:1177–206.PubMed
16.
Zurück zum Zitat Barillari P, Bolognese A, Chirletti P, Cardi M, Sammartino P, Stipa V. Role of CEA, TPA, and Ca 19-9 in the early detection of localized and diffuse recurrent rectal cancer. Dis Colon Rectum. 1992;35:471–6.CrossRefPubMed Barillari P, Bolognese A, Chirletti P, Cardi M, Sammartino P, Stipa V. Role of CEA, TPA, and Ca 19-9 in the early detection of localized and diffuse recurrent rectal cancer. Dis Colon Rectum. 1992;35:471–6.CrossRefPubMed
17.
Zurück zum Zitat Ueda T, Shimada E, Urakawa T. The clinicopathologic features of serum CA 19-9-positive colorectal cancers. Surg Today. 1994;24:518–25.CrossRefPubMed Ueda T, Shimada E, Urakawa T. The clinicopathologic features of serum CA 19-9-positive colorectal cancers. Surg Today. 1994;24:518–25.CrossRefPubMed
18.
Zurück zum Zitat JSCCR. Japanese Classification of Colorectal Carcinoma Second English Edition. Japanese Society for Cancer of the Colon and Rectum. 2009. JSCCR. Japanese Classification of Colorectal Carcinoma Second English Edition. Japanese Society for Cancer of the Colon and Rectum. 2009.
19.
Zurück zum Zitat Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.PubMed Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.PubMed
21.
Zurück zum Zitat Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839–43.PubMed Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839–43.PubMed
22.
Zurück zum Zitat Chan I, Wells W 3rd, Mulkern RV, Haker S, Zhang J, Zou KH, et al. Detection of prostate cancer by integration of line-scan diffusion, T2-mapping and T2-weighted magnetic resonance imaging; a multichannel statistical classifier. Med Phys. 2003;30:2390–8.CrossRefPubMed Chan I, Wells W 3rd, Mulkern RV, Haker S, Zhang J, Zou KH, et al. Detection of prostate cancer by integration of line-scan diffusion, T2-mapping and T2-weighted magnetic resonance imaging; a multichannel statistical classifier. Med Phys. 2003;30:2390–8.CrossRefPubMed
23.
Zurück zum Zitat Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561–77.PubMed Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561–77.PubMed
24.
Zurück zum Zitat Baker SG. The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J Natl Cancer Inst. 2003;95:511–5.CrossRefPubMed Baker SG. The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J Natl Cancer Inst. 2003;95:511–5.CrossRefPubMed
25.
Zurück zum Zitat Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293:1737–45.CrossRefPubMed Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293:1737–45.CrossRefPubMed
26.
Zurück zum Zitat Gardner IA, Greiner M. Receiver-operating characteristic curves and likelihood ratios: improvements over traditional methods for the evaluation and application of veterinary clinical pathology tests. Vet Clin Pathol. 2006;35:8–17.CrossRefPubMed Gardner IA, Greiner M. Receiver-operating characteristic curves and likelihood ratios: improvements over traditional methods for the evaluation and application of veterinary clinical pathology tests. Vet Clin Pathol. 2006;35:8–17.CrossRefPubMed
27.
Zurück zum Zitat Simel DL, Samsa GP, Matchar DB. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol. 1991;44:763–70.CrossRefPubMed Simel DL, Samsa GP, Matchar DB. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol. 1991;44:763–70.CrossRefPubMed
28.
Zurück zum Zitat Choi BC. Slopes of a receiver operating characteristic curve and likelihood ratios for a diagnostic test. Am J Epidemiol. 1998;148:1127–32.PubMed Choi BC. Slopes of a receiver operating characteristic curve and likelihood ratios for a diagnostic test. Am J Epidemiol. 1998;148:1127–32.PubMed
29.
Zurück zum Zitat Fischer JE, Bachmann LM, Jaeschke R. A readers’ guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med. 2003;29:1043–51.CrossRefPubMed Fischer JE, Bachmann LM, Jaeschke R. A readers’ guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med. 2003;29:1043–51.CrossRefPubMed
30.
Zurück zum Zitat Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–72 (discussion 207–12).CrossRefPubMed Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–72 (discussion 207–12).CrossRefPubMed
31.
Zurück zum Zitat Lokich J, Ellenberg S, Gerson B, Knox WE, Zamcheck N. Plasma clearance of carcinoembryonic antigen following hepatic metastatectomy. J Clin Oncol. 1984;2:462–5.PubMed Lokich J, Ellenberg S, Gerson B, Knox WE, Zamcheck N. Plasma clearance of carcinoembryonic antigen following hepatic metastatectomy. J Clin Oncol. 1984;2:462–5.PubMed
32.
Zurück zum Zitat Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266–70.CrossRefPubMed Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266–70.CrossRefPubMed
33.
Zurück zum Zitat Yoshimasu T, Maebeya S, Suzuma T, Bessho T, Tanino H, Arimoto J, et al. Disappearance curves for tumor markers after resection of intrathoracic malignancies. Int J Biol Markers. 1999;14:99–105.PubMed Yoshimasu T, Maebeya S, Suzuma T, Bessho T, Tanino H, Arimoto J, et al. Disappearance curves for tumor markers after resection of intrathoracic malignancies. Int J Biol Markers. 1999;14:99–105.PubMed
34.
Zurück zum Zitat Korner H, Soreide K, Stokkeland PJ, Soreide JA. Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis. Ann Surg Oncol. 2007;14:417–23.CrossRefPubMed Korner H, Soreide K, Stokkeland PJ, Soreide JA. Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis. Ann Surg Oncol. 2007;14:417–23.CrossRefPubMed
35.
Zurück zum Zitat Park IJ, Choi GS, Lim KH, Kang BM, Jun SH. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: Clinical significance of the preoperative level. Ann Surg Oncol. 2009;16:3087–93.CrossRefPubMed Park IJ, Choi GS, Lim KH, Kang BM, Jun SH. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: Clinical significance of the preoperative level. Ann Surg Oncol. 2009;16:3087–93.CrossRefPubMed
36.
Zurück zum Zitat Nakayama T, Watanabe M, Teramoto T, Kitajima M. CA19-9 as a predictor of recurrence in patients with colorectal cancer. J Surg Oncol. 1997;66:238–43.CrossRefPubMed Nakayama T, Watanabe M, Teramoto T, Kitajima M. CA19-9 as a predictor of recurrence in patients with colorectal cancer. J Surg Oncol. 1997;66:238–43.CrossRefPubMed
37.
Zurück zum Zitat Yamashita K, Watanabe M. Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci. 2009;100:195–9.CrossRefPubMed Yamashita K, Watanabe M. Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci. 2009;100:195–9.CrossRefPubMed
Metadaten
Titel
Clinical Significance of CEA and CA19-9 in Postoperative Follow-up of Colorectal Cancer
verfasst von
Tomomi Yakabe, MD
Yuji Nakafusa, MD, PhD
Kenji Sumi, MD, PhD
Atsushi Miyoshi, MD, PhD
Yoshihiko Kitajima, MD, PhD
Seiji Sato, MD, PhD
Hirokazu Noshiro, MD, PhD
Kohji Miyazaki, MD, PhD
Publikationsdatum
01.09.2010
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1004-5

Weitere Artikel der Ausgabe 9/2010

Annals of Surgical Oncology 9/2010 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.